The Catalyst

New Documentary Highlights Tremendous Advances in Cancer Treatment

Posted by Guest Contributor on March 30, 2015 at 12:30 PM

Cancer will touch the lives of most Americans, but few understand its history. Cancer: The Emperor of All Maladies, a biography of the disease by award-winning filmmaker Ken Burns, takes on the challenge of explaining the impact of a disease which has been around since the beginning of time, and will strike more than 1.6 million Americans in 2015 alone.

Read More

Topics: cancer, Oncology, PBS

Medicare Monday: Gaining Part D Coverage Reduces Hospitalizations and Overall Spending in Medicare

Posted by Allyson Funk on March 30, 2015 at 9:18 AM

As you learned in last week’s video, Medicare Part D helps seniors adhere to their medicines by providing access to prescription drug coverage. This helps beneficiaries live healthier lives by avoiding use of more costly medical services, which helps reduce spending in the broader health care ecosystem.

Here’s one example: according to a recent study from Johns Hopkins University and the University of Illinois, gaining prescription medicine coverage through Medicare Part D was tied to an eight percent decrease in hospital admissions for seniors.

Patients with artery plaque, congestive heart failure, chronic obstructive pulmonary disease and dehydration have especially benefited from a decrease in hospitalizations. Here are some examples of how beneficiaries are realizing the value of their Part D coverage.

Read More

Topics: #MedicareMonday, health care spending, hospitals

Week in Review: The Latest from PhRMA

Posted by Allyson Funk on March 27, 2015 at 3:00 PM

New report on intellectual property, 5 things you should know about Medicare Part D, and more

Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending - The biopharmaceutical industry comes out on top as the country’s manufacturing leader in innovation and economic contributions in a new report from ndp│analytics. According to the analysis, the industry had the highest research and development (R&D) investment over the last decade, accounting for 27 percent of average annual R&D spending from 2000-2012.

Read More

Topics: Value, R&D, Week in Review, 340B, Medicare

Week in Review: Building a Brighter Future for Patients

Posted by Christian Clymer on March 27, 2015 at 10:32 AM

When it comes to patient health and well-being, today’s treatment advancements are borne from and stand on the shoulders of investment in prior research and development (R&D).

As science continues to evolve, our industry is always imagining new discovery frontiers. So, this week, we discussed a few ways we’re focused on what’s next for patients.

Since 1991, cancer survival rates have increased as death rates have fallen 20 percent. On Wednesday, we introduced a new Catalyst series that explores what continued research could mean for the future for cancer patients.

Read More

Topics: adherence, cancer, HHS

Collaboration for Cures: Teaming Up to Advance Science and Save Lives

Posted by Tina Stow on March 26, 2015 at 3:39 PM

“Whether it’s our family, our friends, all of us are potentially patients one day.”

In a single sentence, Dr. Anthony Coyle, senior vice president and chief scientific officer at Pfizer’s Centers for Therapeutic Innovation (CTI), sums up what inspires the researchers and scientists fueling progress at America’s biopharmaceutical companies.

Read More

Topics: Science, Pfizer, NIH, clinical research

Ask About Adherence – Q&A with Prescriptions for a Healthy America

Posted by Samantha Dougherty on March 26, 2015 at 1:06 PM

Ask About Adherence is a blog series featuring Q&A’s with experts on medication adherence. In this post, we speak with Joel White, Prescriptions for a Healthy America president, on the landscape of potential solutions to non-adherence.

Read More

Topics: adherence, #Adherence123s, Ask About Adherence

Supporting Better Patient Outcomes Through Reform

Posted by Holly Campbell on March 25, 2015 at 12:49 PM

Today’s events at the White House and U.S. Department of Health and Human Services (HHS) highlighted the growing interest from policy makers and stakeholders in shifting the health care payment system to support greater quality of care rather than the quantity of care provided to patients.  PhRMA has long supported policies to advance affordable, high-quality, individualized care, and we were pleased to participate in today’s inaugural meeting of the Learning and Action Network (LAN), an initiative of HHS to discuss payment and delivery reform.

Read More

Topics: Value

Healthy Outlook: Conquering Cancer in the 21st Century

Posted by Randy Burkholder on March 25, 2015 at 12:30 PM

We are at a pivotal juncture in cancer care. As highlighted in recent stories from outlets such as The New  York Times, NPR and TIME, advances in science and technology (such as genomics and health information technology) are opening up new opportunities for effectively treating cancer.   Continuing advances in prevention, detection, and treatment are driving up cancer survival rates and enabling people to live longer and healthier lives.  At the same time, we’re in the midst of an important debate about the affordability and cost of cancer care, as well as significant changes in how we pay for and deliver care to cancer patients.

Read More

Topics: cancer

PhRMA Statement on Energy & Commerce Health Subcommittee 340B Hearing

Posted by Allyson Funk on March 24, 2015 at 7:00 AM

Today, PhRMA CEO John J. Castellani sent the following statement for the record to the Energy and Commerce Health Subcommittee on the hearing they’re holding on the 340B program:

Read More

Topics: 340B, House Energy & Commerce Committee

A Life-Saving Life’s Work: A Story on the Impact of Clinical Trials

Posted by Guest Contributor on March 23, 2015 at 4:16 PM

Clinical trials are an essential step in the process to develop new medicines and as they work to bring about lifesaving new treatments, they also contribute to the local economies where they are conducted. In partnership with PhRMA, Battelle produced a new study on the impact of biopharmaceutical-sponsored clinical trials in all 50 states.

Read More

Topics: Economic Impact, Clinical Trials

Personalized Updates

Posts by Topic

see more